KLRC1 and hepatocellular carcinoma: The use of a blocking antibody against NKG2A [257] or an NKG2A protein expression blocker [258], engineered to abrogate NKG2A expression by preventing its translocation to the cell membrane, have proven to be therapeutic in preclinical mouse models, overcoming NK cell resistances, but remain to be tested in HCC.